| Date | Title | Description |
| 17.04.2024 | Parent Project Muscular Dystrophy Celebrates 30th Anniversary with Launch of PPMD Together Meeting Series in Cincinnati, Ohio | PPMD Together: Cincinnati Marks Three Decades of PPMD's Impact and Mayor's Proclamation
Honors Founding President & CEO Pat Furlong's Dedication to the Duchenne Community
CINCINNATI, April 17, 2024 /PRNewswire/ -- Parent Project Muscula... |
| 22.03.2024 | FDA Nod in Duchenne Helps Wider Swath of Patients With the Rare Muscle Disease | Duchenne muscular dystrophy has several approved drugs, including a gene therapy that provides children who have the rare, inherited muscle-wasting disease the option of a one-time treatment. But each of these therapies only treats certain ... |
| 19.10.2023 | Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi | - |
| 07.09.2023 | Australian Patient Advocacy Organization Named a Recipient of PTC Therapeutics' 2023 STRIVE™ Award for Duchenne Muscular Dystrophy | - Grant funding will support Save our Sons Duchenne Foundation in developing a digital health app -
SYDNEY, Sept. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that an Australian patient advocacy organization... |
| 17.05.2023 | PTC Posts Positive Phase 3 Data, But Comparison to BioMarin Is Less Clear | A PTC Therapeutics drug in development for an inherited metabolic disorder has achieved the main goal of a pivotal study, results that support bringing the therapy to regulators. But less clear is how the drug will match up against a BioMar... |
| 08.02.2022 | PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results | SOUTH PLAINFIELD, N.J., Feb. 8, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and year-end 2021 financial results and provide an ... |
| 25.01.2022 | FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy | SOUTH PLAINFIELD, N.J., Jan. 25, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for Evrys... |
| 18.01.2022 | PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community | SOUTH PLAINFIELD, N.J., Jan. 18, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the eighth annual STRIVE™ awards program for Duchenne muscular dystrophy (Duchenne). Through this program, PTC provide... |
| 14.01.2022 | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH PLAINFIELD, N.J., Jan. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 7, 2022, the company approved non-statutory stock options to purchase an aggregate of 18,255 shares of its common stock... |
| 13.01.2022 | PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program | SOUTH PLAINFIELD, N.J., Jan. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the company's 2022 Talent Pipeline Program, a one-year, global initiative designed to provide recent college graduates... |
| 10.01.2022 | PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference | SOUTH PLAINFIELD, N.J., Jan. 10, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 40th Annual J.P. Morgan Healthcare Conference today, Monday Jan. 10th ... |
| 04.01.2022 | Waylivra™ Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil | SOUTH PLAINFIELD, N.J., Jan. 4, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Waylivra™ (volanesorsen) has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos... |
| 03.01.2022 | PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference | SOUTH PLAINFIELD, N.J., Jan. 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Monday, Jan. 10, at 7... |
| 20.12.2021 | Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform | SOUTH PLAINFIELD, N.J., Dec. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the Nature Communications publication characterizing the novel splicing mechanism induced by compounds identified from the Huntingto... |
| 06.12.2021 | Evrysdi® Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery | SOUTH PLAINFIELD, N.J., Dec. 6, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi® (risdiplam) has received multiple awards that recognize it as one of the most innovative therapies of 2021 and for its ... |
| 03.12.2021 | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH PLAINFIELD, N.J., Dec. 2, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 29, 2021, the company approved non-statutory stock options to purchase an aggregate of 83,750 shares of its common stock... |
| 16.11.2021 | PTC Therapeutics to Participate at Upcoming Virtual Investor Conference | SOUTH PLAINFIELD, N.J., Nov. 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m... |
| 28.10.2021 | PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results | SOUTH PLAINFIELD, N.J., Oct. 28, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2021.
"The stellar growth of our DMD franch... |
| 26.10.2021 | PTC Therapeutics to Participate at Upcoming Virtual Investor Conference | SOUTH PLAINFIELD, N.J., Oct. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, Nov. 9 at 8:00 a.... |
| 25.10.2021 | PTC Therapeutics : Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil | SOUTH PLAINFIELD, N.J., Oct. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian National Health Surveillance Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved the expansio... |
| 18.10.2021 | HILA approves access to Translarna™ the first treatment approved for the underlying cause of childhood muscle wasting disease | HILA approves access to Translarna™ the first treatment approved for the underlying cause of childhood muscle wasting disease Mon, Oct 18, 2021 06:00 CET
- Decision by the Finnish Pharmaceuticals Pricing Board (HILA) means access for ambula... |
| 14.10.2021 | PTC Therapeutics : Celebrates Opening of Gene Therapy Manufacturing Facility | SOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing facility in Hopewell, N.J. today at 4 p.... |
| 14.10.2021 | PTC Therapeutics : to Host Conference Call to Discuss Third Quarter 2021 Financial Results | SOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2021 financial results and provide an update on the... |
| 11.10.2021 | PTC Therapeutics : Tegsedi® Receives Innovative Drug Category Pricing in Brazil | SOUTH PLAINFIELD, N.J., Oct. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tegsedi® (inotersen) has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - ... |
| 23.08.2021 | PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome | |
| 23.08.2021 | PTC Therapeutics : Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome | SOUTH PLAINFIELD, N.J., Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra™ (volanesorsen... |
| 29.07.2021 | PTC Therapeutics : Provides a Corporate Update and Reports Second Quarter 2021 Financial Results | SOUTH PLAINFIELD, N.J., July 29, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2021.
"I am delighted to say all facets of our ... |
| 29.07.2021 | PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results | |
| 26.05.2021 | PTC THERAPEUTICS, INC.
PTC Therapeutics : Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia | SOUTH PLAINFIELD, N.J., May 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD... |
| 17.05.2021 | PTC Therapeutics : New Data Shows Devastating Impact of AADC Deficiency on Caregivers | SOUTH PLAINFIELD, N.J., May 17, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data from the first study on the impact of caring for a child with the ultra-rare genetic disorder, aromatic L-Amino acid decarboxyla... |
| 04.05.2021 | PTC Therapeutics : Provides a Corporate Update and Reports First Quarter 2021 Financial Results | SOUTH PLAINFIELD, N.J., May 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2021.
"Overall PTC has had a strong performance t... |
| 01.05.2021 | PTC THERAPEUTICS, INC.
PTC Therapeutics : 2020 Annual Report | 2020 Annual Report
youHERE FOR
OUR PROMISE. Rare diseases, real strides to treat them-this is why we're here. No matter how uncommon the disorder, the life-limiting effects are a daily reality for those affected. When Stu Peltz founded PTC ... |
| 14.04.2021 | PTC THERAPEUTICS, INC.
PTC Therapeutics : Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing | SOUTH PLAINFIELD, N.J., April 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United States for individuals who have symptoms consistent with, or a di... |
| 01.04.2021 | PTC THERAPEUTICS, INC.
PTC Therapeutics : Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™ | SOUTH PLAINFIELD, N.J., April 1, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the European Union under ... |
| 30.03.2021 | PTC THERAPEUTICS, INC.
PTC Therapeutics : Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy | SOUTH PLAINFIELD, N.J., March 30, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the European Commission (EC) has granted marketing authorization to Evrysdi™ (risdiplam) for the treatment of spinal muscular ... |
| 09.03.2021 | Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine | NEW YORK and SOUTH PLAINFIELD, N.J., March 9, 2021 /PRNewswire/ -- The Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics, Inc. (NASDAQ: PTCT) have entered into a new collaboration focused on regenerative medicine to further adva... |
| 09.03.2021 | Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine | NEW YORK and SOUTH PLAINFIELD, N.J., March 9, 2021 /PRNewswire/ -- The Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics, Inc. (NASDAQ: PTCT) have entered into a new collaboration focused on regenerative medicine to further adva... |
| 26.02.2021 | PTC Therapeutics : Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update | SOUTH PLAINFIELD, N.J., Feb. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the fourth quarter and full year ending December 31, 2020 and provided a corporate update.
"Despite the c... |
| 25.02.2021 | PTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update | SOUTH PLAINFIELD, N.J., Feb. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the fourth quarter and full year ending December 31, 2020 and provided a corporate update.
"Despite the c... |
| 24.02.2021 | Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of Medicine | SOUTH PLAINFIELD, N.J., Feb. 24, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the publication of results from the dose finding Part 1 of the pivotal FIREFISH study evaluating Evrysdi™ (risdiplam) in infants wi... |
| 14.01.2021 | PTC THERAPEUTICS, INC.
PTC Therapeutics : Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category | SOUTH PLAINFIELD, N.J., Jan. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the seventh annual STRIVE Awards program for Duchenne muscular dystrophy. The Awards provide a grant to patient advoca... |
| 14.01.2021 | PTC Therapeutics : Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category | SOUTH PLAINFIELD, N.J., Jan. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the seventh annual STRIVE Awards program for Duchenne muscular dystrophy. The Awards provide a grant to patient advoca... |
| 10.08.2020 | FDA approves Roche, PTC drug for spinal muscular atrophy | Shares of PTC were up less than 2% on the Nasdaq on Monday afternoon.
“We started looking for treatments for SMA more than a decade ago,” SMA Foundation President Loren Eng said in a statement. “PTC was one of the companies that embraced an... |
| 17.06.2020 | PTC receives go-ahead from FDA to test cancer drug in Covid-19 | The drug is in a 39-patient Phase Ib study in relapsed and refractory acute myeloid leukemia that opened in October 2018, according to the ClinicalTrials.gov database. The primary completion date was late last month, and the estimated compl... |
| 26.08.2019 | They rallied around ‘our boys’ as they pushed for a Duchenne cure. Where did that leave girls? | Deb and Shawn Jenssen were used to frustration. Their kids had been turned away from studies. Doctors had questioned if they could really be showing signs of a disease even as it made it harder for them to walk.
All of it helped explain why... |
| 01.07.2019 | Updated: Lonza sets sights on expansion, buying Novartis facility; IQVIA leads $14 million Series B funding round | → Lonza Pharma & Biotech is expanding, buying up a Swiss facility Novartis has been using to produce drug vials and plugging it into their global supply network for industry clients. As is often the case with these d... |
| 28.06.2019 | Unfazed by failure, PTC Therapeutics to appeal negative EMA decision on its disaster prone Duchenne drug | PTC Therapeutics’ bid to expand the approval of its Duchenne muscular dystrophy drug in Europe has been unsuccessful. The New Jersey-based drugmaker is not known for taking no for an answer and will appeal the decision... |
| 04.02.2019 | ‘We’re still waiting’: As cystic fibrosis drugs deliver new hope, not everyone is being swept up by scientific progress | CAMBRIDGE, Mass. — The tiny round one is vitamin K. There’s a gel cap (vitamin D), a two-tone capsule (that one protects his liver), a square pill (generic Singulair), and more — seven pill bottles sharing space on his dresser with a “Crimi... |
| 01.08.2017 | Is the FDA telegraphing a rejection for PTC Therapeutics’ DMD drug? | The FDA’s once-raging internal debate over Sarepta Therapeutics has cooled, but a recently unearthed document might portend failure for the next company angling to win an approval in Duchenne muscular dystrophy.
PTC Therapeutics is seeking ... |
| 21.04.2017 | Another controversial drugmaker just left the industry's most powerful lobby | Reuters
President Donald Trump and PhRMA president Steve Ubl.
Marathon Pharmaceuticals is no longer a member of the powerful pharmaceutical lobby, the Pharmaceutical Research and Manufacturers of America, or PhRMA, the group said.
The compa... |
| 25.03.2017 | Knopp Biosciences Announces Election of Biotech Executive Shane Kovacs to Board of Managers | Knopp Biosciences announced the appointment of Shane Kovacs to its Board of Managers. Kovacs joins the board as the the company initiates advanced clinical development of dexpramipexole in hypereosinophilic syndrome (HES) and eosinophilic a... |
| 11.11.2016 | PTC shares rocket up as European regulators offer a thumbs-up on Duchenne drug marketing | PTC Therapeutics CEO Stuart Peltz
A few days after warning investors of the rising uncertainty it faced in the ongoing European review of its conditional approval for Translarna, shares of PTC Therapeutics $PTCT sky... |
| 17.10.2016 | PTC shares plunge anew after FDA slaps down Duchenne drug for a second time | PTC Therapeutics CEO Stuart Peltz
There will be no Lazarus-like rise from the dead for PTC Therapeutics at the FDA — at least for now. The agency has slapped down the biotech’s first appeal of the FDA’s refusal to even consider w... |
| 24.02.2016 | FDA rejects application for Duchenne drug, rattling investors and parents | Yet another company developing a drug for Duchenne muscular dystrophy suffered a setback as PTC Therapeutics disclosed yesterday that the Food and Drug Administration rejected its application for its experimental treatment. The move is also... |
| 14.04.2015 | Duchenne Muscular Dystrophy market to shoot up 100-fold in five years | “These mutation-specific drugs are expected to have a high price point due to their novelty, efficacy and orphan drug status, and will contribute 85.6% to the DMD treatment arena by 2019,” GlobalData analyst Nikhilesh Sanyal said in a state... |
| 20.06.2013 | PTC Therapeutics joins the IPO scrum as more biotechs take advantage of receptive market | The nonsense mutation is the cause of Duchenne muscular dystrophy in about 13 percent of patients, or 2,000 people in the United States and 2,500 in the European Union. The company also plans to treat nonsense mutations in other genetic dis... |
| 10.06.2013 | For new Rhode Island firm, peptides hold hope for disease-altering cystic fibrosis treatments | Procaftor, Calista’s lead candidate, is designed to restore function to the CFTR transporter in the lungs and prevent the buildup of thick mucus. President and CEO Andrew Mallon said that preclinical studies have suggested clinical efficacy... |
| 07.03.2013 | PTC Therapeutics Completes $60M Financing | PTC Therapeutics, Inc., a South Plainfield, NJ-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small-molecule drugs that target post-transcriptional control pro... |
| 23.07.2012 | Late-stage cystic fibrosis, muscular dystrophy drug raises $30 million | With cystic fibrosis the goal is to improve lung function and reduce pulmonary exacerbation. In a Phase 3 clinical study, Ataluren demonstrated trends in improvement in lung function when compared to a placebo. There were also trends in imp... |
| 23.07.2012 | PTC Therapeutics Completes $30M Financing | PTC Therapeutics, Inc. (PTC), a South Plainfield, NJ-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes,... |
| 14.06.2012 | Drug developer with phase 3 cystic fibrosis treatment raising $40 million | South Plainfield, New Jersey-based PTC Therapeutics‘ drug Ataluren was given orphan drug status by the U.S. Food and Drug Administration and the European Commission to treat nonsense mutation cystic fibrosis and nonsense mutation Duchenne a... |
| 16.04.2012 | Amicus Therapeutics names new CFO | Currently, Genzyme is the only other company that provides a drug for this disease since Shire dropped its efforts to get the drug approved after years of back-and-forth with the U.S. Food and Drug Administration.
The Cranbury, New Jersey-b... |
| 23.12.2011 | PTC Therapeutics Receives $5M Seeding Drug Discovery (SDD) Award from the Wellcome Trust | PTC Therapeutics, Inc., a South Plainfield, NJ-based biopharmaceutical company has received a $5m Seeding Drug Discovery (SDD) Award from the Wellcome Trust.
The company intends to use the funding for the development of small-molecule drugs... |
| 22.12.2011 | PTC Therapeutics gets $5 million drug development award | Of the 1.7 million hospital-acquired bacterial infections that cause or contribute to nearly 100,000 deaths in the United States each year, according to estimates from the Centers for Disease Control and Prevention, Gram-negative bacteria a... |
| 29.11.2011 | PTC Therapeutics licensing agreement with Roche valued up to $490 million | PTC Therapeutics has agreed to a licensing deal with Swiss pharmaceutical firm Roche for its spinal muscular atrophy program that could be worth as much as $490 million.
Under the terms of the agreement, Roche gains an exclusive worldwide l... |
| 23.04.2007 | The boulevard of broken IPO dreams | Dollars may be sluicing into biotechnology via venture investments and acquisitions these days, but there’s still one place that private biotechs can’t seem to catch a break, and that’s in the public markets.
The latest casualty here is PTC... |
| - | FDA approves Roche, PTC drug for spinal muscular atrophy | The Food and Drug Administration has approved the latest entrant into the market for drugs to treat spinal muscular atrophy.
South Plainfield, New Jersey-based PTC Therapeutics said Friday that the FDA had approved Evrysdi (risdiplam) as th... |
| - | CHMP Adopts Positive Opinion for Evrysdi™ for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older | SOUTH PLAINFIELD, N.J., Feb. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evry... |
| - | PTC receives go-ahead from FDA to test cancer drug in Covid-19 | Drugs in development for Covid-19 generally fall into two categories: antivirals that go after the SARS-CoV-2 virus itself and anti-inflammatory agents that address the hyperactive immune system response associated with the most serious sym... |
| - | PTC Therapeutics licensing agreement with Roche valued up to $490 million | PTC Therapeutics has agreed to a licensing deal with Swiss pharmaceutical firm Roche for its spinal muscular atrophy program that could be worth as much as $490 million.
Under the terms of the agreement, Roche gains an exclusive worldwide l... |
| - | Late-stage cystic fibrosis, muscular dystrophy drug raises $30 million | A biopharmaceutical company with a cystic fibrosis drug in late-stage development has raised $30 million, according to a company statement. It was about $10 million less than the original funding target listed in a form D document with the ... |
| - | Drug developer with phase 3 cystic fibrosis treatment raising $40 million | A drug developer that recently reported positive phase 3 results for its cystic fibrosis treatment for a severe form of the genetic disorder is raising $40 million in equity, according to a Form D filing with the U.S. Securities and Exchang... |
| - | For new Rhode Island firm, peptides hold hope for disease-altering cystic fibrosis treatments | It’s been nearly two-and-a-half decades since the gene associated with the inherited disease cystic fibrosis was discovered, paving the way for disease-modifying drugs. In that time, only one such drug has been approved in the U.S. and Euro... |
| - | PTC Therapeutics gets $5 million drug development award | PTC Therapeutics has received a $5 million Seeding Drug Discovery award from UK charity Wellcome Trust to support the development of small-molecule drugs to battle life-threatening infections caused by multi-drug-resistant, Gram-negative ba... |
| - | Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients | SOUTH PLAINFIELD, N.J., March 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced two-year data from Part 2 of the SUNFISH trial evaluating Evrysdi™ (risdiplam) in children and adults with Type 2 or Type 3 spinal ... |
| - | PTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies | SOUTH PLAINFIELD, N.J., March 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from a real-world study of patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) who switched... |
| - | Amicus Therapeutics names new CFO | Amicus Therapeutics (NASDAQ:FOLD) has hired a biopharmaceutical industry veteran as chief financial officer of its business to develop treatments for lysosomal storage diseases and neurodegenerative diseases.
William D. Baird III previously... |
| - | Duchenne Muscular Dystrophy market to shoot up 100-fold in five years | As a whole host of new Duchenne Muscular Dystrophy therapies mature down the regulatory pathway, the global market for the degenerative disease is expected to expand at an incredible rate – from $8.2 million in 2014 to $990 million in 2019,... |
| - | PTC Therapeutics joins the IPO scrum as more biotechs take advantage of receptive market | It may not be the most complimentary assessment of a biotech’s initial public offering to say that if PTC Therapeutics can reach its public offering target of $125 million, then the market really is coming back for IPOs. But to be sure, the... |